4th Quarter - Report

EXPRESS SCRIPTS, INC. for EXPRESS SCRIPTS, INC.

Firm
Client
Income
—
Expenses
$830,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Implementation of tax provisions of the ACA, including the insurer tax. Tax reform policies.

LobbyistCovered position, as disclosed
CHRISTOPHER DAVIS —
JONAH C HOUTS —
EMILY A KATZ —
GARY J KLINE —
SERGIO SANTIVIAGO —

Contacted: Government Accountability Office (GAO); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); Internal Revenue Service (IRS); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA); Office of Personnel Management (OPM); Federal Trade Commission (FTC); Labor, Dept of (DOL); SENATE; White House Office; Congressional Budget Office (CBO); Executive Office of the President (EOP); Medicare Payment Advisory Commission (MedPAC)

Defense DEF

Pharmacy issues related to the annual defense authorization and implementation of the 2017 NDAA.

LobbyistCovered position, as disclosed
CHRISTOPHER DAVIS —
MICHAEL DONNELLY —
JONAH C HOUTS —
EMILY A KATZ —
GARY J KLINE —
LISA CHRISTINE LE GETTE New —
SERGIO SANTIVIAGO —

Contacted: Medicare Payment Advisory Commission (MedPAC); Internal Revenue Service (IRS); Federal Trade Commission (FTC); White House Office; Government Accountability Office (GAO); SENATE; Office of Personnel Management (OPM); Health Resources & Services Administration (HRSA); Congressional Budget Office (CBO); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); Labor, Dept of (DOL); Health & Human Services, Dept of (HHS)

Health Issues HCR

Regulatory policies related to the health reform law, including drug benefits and disclosure. Implementation of HITECH. Prescription drug affordability issues. Reforms to Medicaid and Exchange markets.

LobbyistCovered position, as disclosed
CHRISTOPHER DAVIS —
JONAH C HOUTS —
EMILY A KATZ —
GARY J KLINE —
SERGIO SANTIVIAGO —

Contacted: Executive Office of the President (EOP); Food & Drug Administration (FDA); Health Resources & Services Administration (HRSA); Labor, Dept of (DOL); Health & Human Services, Dept of (HHS); Internal Revenue Service (IRS); Federal Trade Commission (FTC); HOUSE OF REPRESENTATIVES; Office of Personnel Management (OPM); Congressional Budget Office (CBO); Government Accountability Office (GAO); SENATE; White House Office; Centers For Medicare and Medicaid Services (CMS); Medicare Payment Advisory Commission (MedPAC)

Medicare/Medicaid MMM

Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations.

LobbyistCovered position, as disclosed
CHRISTOPHER DAVIS —
JONAH C HOUTS —
EMILY A KATZ —
GARY J KLINE —
LISA CHRISTINE LE GETTE New —
SERGIO SANTIVIAGO —

Contacted: Federal Trade Commission (FTC); Health & Human Services, Dept of (HHS); Internal Revenue Service (IRS); Executive Office of the President (EOP); SENATE; Government Accountability Office (GAO); Labor, Dept of (DOL); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Medicare Payment Advisory Commission (MedPAC); HOUSE OF REPRESENTATIVES; White House Office; Office of Personnel Management (OPM); Health Resources & Services Administration (HRSA); Congressional Budget Office (CBO)

Bills named: S. 637 (115th), H.R. 1920 (115th), H.R. 1939 (115th)

Pharmacy PHA

Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.

LobbyistCovered position, as disclosed
CHRISTOPHER DAVIS —
JONAH C HOUTS —
EMILY A KATZ —
GARY J KLINE —
LISA CHRISTINE LE GETTE New —
SERGIO SANTIVIAGO —

Contacted: Executive Office of the President (EOP); Congressional Budget Office (CBO); Labor, Dept of (DOL); Health Resources & Services Administration (HRSA); Food & Drug Administration (FDA); SENATE; Medicare Payment Advisory Commission (MedPAC); Health & Human Services, Dept of (HHS); White House Office; Federal Trade Commission (FTC); Office of Personnel Management (OPM); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Government Accountability Office (GAO); Internal Revenue Service (IRS)

Bills named: H.R. 1854 (115th), H.R. 2025 (115th), S. 788 (115th)

Affiliated organisations

OrganisationLocation
EVICORE Bluffton, SC, US

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.